News|Articles|October 7, 2024
A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic
Author(s)Catalent
Harmonizing technological innovation and a platform approach in biomanufacturing can reduce time and cost barriers to produce stable, high-expressing antibody-based therapeutics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
2
How Biopharma Navigates the 2026 Economic Shift
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5